These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21804623)

  • 1. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
    Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M
    Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.
    Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT).
    Václavík J; Sedlák R; Jarkovský J; Kociánová E; Táborský M
    Medicine (Baltimore); 2014 Dec; 93(27):e162. PubMed ID: 25501057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial.
    Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):384-90. PubMed ID: 23235719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
    Oxlund CS; Henriksen JE; Tarnow L; Schousboe K; Gram J; Jacobsen IA
    J Hypertens; 2013 Oct; 31(10):2094-102. PubMed ID: 24107738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
    Lim PO; Jung RT; MacDonald TM
    Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.
    Shlomai G; Sella T; Sharabi Y; Leibowitz A; Grossman E
    Hypertens Res; 2014 Dec; 37(12):1037-41. PubMed ID: 24671013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
    Williams B; MacDonald TM; Morant S; Webb DJ; Sever P; McInnes G; Ford I; Cruickshank JK; Caulfield MJ; Salsbury J; Mackenzie I; Padmanabhan S; Brown MJ;
    Lancet; 2015 Nov; 386(10008):2059-2068. PubMed ID: 26414968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
    Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study.
    Rosa J; Widimský P; Waldauf P; Zelinka T; Petrák O; Táborský M; Branny M; Toušek P; Čurila K; Lambert L; Bednář F; Holaj R; Štrauch B; Václavík J; Kociánová E; Nykl I; Jiravský O; Rappová G; Indra T; Krátká Z; Widimský J
    J Hypertens; 2017 May; 35(5):1093-1099. PubMed ID: 28118281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of Propranolol in Resistant Arterial hypertension Treatment (APROPRIATE study): study protocol for a randomized double-blind placebo-controlled trial.
    Constantine GR; Ranasinghe P; Weeratunga P; Weeraratne C; Galappatthy P; Rajapakse S; Senarath U; Katulanda P
    Trials; 2017 Mar; 18(1):124. PubMed ID: 28292320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population.
    Djoumessi RN; Noubiap JJ; Kaze FF; Essouma M; Menanga AP; Kengne AP; Mbanya JC; Sobngwi E
    BMC Res Notes; 2016 Mar; 9():187. PubMed ID: 27007793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.